Literature DB >> 11788127

Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism.

J C Fruchart1.   

Abstract

Recently, considerable progress has been made in understanding the molecular basis of lipoprotein metabolism, including the role of peroxisome proliferator-activated receptor (PPAR)-alpha--the specific transcription factor which, when activated, influences the expression of genes encoding for proteins involved in high-density lipoprotein (HDL) metabolism. Because the fibrates have a direct effect on PPAR-alpha and, in turn, on 5 key genes that determine lipoprotein structure and function, they are able to exert a multiple influence on HDL metabolism. Increased HDL synthesis, accelerated efflux of cholesterol, and its hepatic uptake are the ultimate outcome of fibrate influence, with a consequent enhancement of the protective effect of HDL cholesterol.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11788127     DOI: 10.1016/s0002-9149(01)02149-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  13 in total

Review 1.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Serum choline plasmalogens, particularly those with oleic acid in sn-2, are associated with proatherogenic state.

Authors:  Megumi Nishimukai; Ryouta Maeba; Yuya Yamazaki; Toru Nezu; Toshihiro Sakurai; Yuji Takahashi; Shu-Ping Hui; Hitoshi Chiba; Tomoki Okazaki; Hiroshi Hara
Journal:  J Lipid Res       Date:  2014-03-10       Impact factor: 5.922

Review 3.  PPAR ligands: potential therapies for metabolic syndrome.

Authors:  Taro E Akiyama; Peter T Meinke; Joel P Berger
Journal:  Curr Diab Rep       Date:  2005-02       Impact factor: 4.810

Review 4.  Drug treatment of hyperlipidaemia: a guide to the rational use of lipid-lowering drugs.

Authors:  Peter P Toth
Journal:  Drugs       Date:  2010-07-30       Impact factor: 9.546

5.  "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Authors:  Alexander Tenenbaum; Enrique Z Fisman
Journal:  Cardiovasc Diabetol       Date:  2010-06-15       Impact factor: 9.951

Review 6.  Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review.

Authors:  Prabal K Chatterjee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-22       Impact factor: 3.000

7.  The effects of simultaneous administration of dietary conjugated linoleic acid and telmisartan on cardiovascular risks in rats.

Authors:  Mohammad M Abdullah; Zuyuan Xu; Grant N Pierce; Mohammed H Moghadasian
Journal:  Lipids       Date:  2007-08-07       Impact factor: 1.880

8.  Raising HDL cholesterol in women.

Authors:  Danny J Eapen; Girish L Kalra; Luay Rifai; Christina A Eapen; Nadya Merchant; Bobby V Khan
Journal:  Int J Womens Health       Date:  2010-08-09

Review 9.  Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.

Authors:  Alexander Tenenbaum; Enrique Z Fisman; Michael Motro; Yehuda Adler
Journal:  Cardiovasc Diabetol       Date:  2006-09-26       Impact factor: 9.951

10.  Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?

Authors:  Alexander Tenenbaum; Enrique Z Fisman
Journal:  Cardiovasc Diabetol       Date:  2004-12-01       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.